Cocrystal Pharma, Inc. (COCP)
NCM · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is a phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, an HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was headquartered in Bothell, Washington.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 225K |
| Operating Income | -2.1M | -2.1M | -2.5M | -2.4M |
| Net Income | -2.1M | -2.0M | -2.4M | -2.3M |
| Diluted EPS | $-0.20 | $-0.19 | $nan | $-0.17 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -18.1M | -21.2M | -17.9M | -9.0M |
| Net Income | -38.8M | -18.0M | -17.5M | -8.8M |
| Diluted EPS | $-4.77 | $-1.87 | $-1.72 | $-0.78 |